Prostate-specific antigen and other serum and urine markers in prostate cancer.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Biochimica et Biophysica Acta

• Publication date

  2014-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.bbcan.2014.04.001PMID 24727384
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Surveillance for certain health behaviors among states and selected local areas--Behavioral Risk Factor Surveillance System, United States, 2011.

  2014cited by this paper
• Cancer statistics, 2014

  2014cited by this paper
• Sarcosine and other metabolites along the choline oxidation pathway in relation to prostate cancer—A large nested case–control study within the JANUS cohort in Norway

  2014cited by this paper
• Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.

  2014cited by this paper
• PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study.

  2013cited by this paper
• Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) Significantly Improve Prostate Cancer Detection at Initial Biopsy in a Total PSA Range of 2–10 ng/ml

  2013cited by this paper
• Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer.

  2013cited by this paper
• Prostate Health Index (PHI): golden bullet or just another prostate cancer marker?

  2013cited by this paper
• Evolution of novel biomarkers for detection of prostate cancer.

  2013cited by this paper
• PCA3 and PCA3-Based Nomograms Improve Diagnostic Accuracy in Patients Undergoing First Prostate Biopsy

  2013cited by this paper
• Serum sarcosine is a risk factor for progression and survival in patients with metastatic castration-resistant prostate cancer.

  2013cited by this paper
• Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay.

  2013cited by this paper
• Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.

  2013cited by this paper
• The mutational landscape of prostate cancer.

  2013cited by this paper
• From prostate‐specific antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of proPSAs in the detection and management of early prostate cancer

  2013cited by this paper
• Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.

  2013cited by this paper
• Comparative effectiveness review: prostate cancer antigen 3 testing for the diagnosis and management of prostate cancer.

  2013cited by this paper
• Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study.

  2013cited by this paper
• Urinary biomarkers for prostate cancer: a review.

  2013cited by this paper
• Risk stratification in prostate cancer screening

  2013cited by this paper
• Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis

  2013cited by this paper
• Use of PCA3 in detecting prostate cancer in initial and repeat prostate biopsy patients

  2013cited by this paper
• Baseline prostate-specific antigen measurements and subsequent prostate cancer risk in the Danish Diet, Cancer and Health cohort.

  2013cited by this paper
• Prospective evaluation of serum sarcosine and risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.

  2013cited by this paper
• Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection

  2013cited by this paper
• Sarcosine as a Potential Prostate Cancer Biomarker—A Review

  2013cited by this paper
• Value of PCA3 to Predict Biopsy Outcome and Its Potential Role in Selecting Patients for Multiparametric MRI

  2013cited by this paper
• Clinical judgment versus biomarker prostate cancer gene 3: which is best when determining the need for repeat prostate biopsy?

  2013cited by this paper
• Surveillance for certain health behaviors among States and selected local areas - United States, 2010.

  2013cited by this paper
• Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer

  2013cited by this paper
• Spondin-2, a secreted extracellular matrix protein, is a novel diagnostic biomarker for prostate cancer.

  2013cited by this paper
• Toward the detection of prostate cancer in urine: a critical analysis.

  2013cited by this paper
• Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy

  2013cited by this paper
• PCA3 in the detection and management of early prostate cancer

  2013cited by this paper
• Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy.

  2013cited by this paper
• Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer.

  2013cited by this paper
• Quantified KLK15 Gene Expression Levels Discriminate Prostate Cancer From Benign Tumors and Constitute a Novel Independent Predictor of Disease Progression

  2013cited by this paper
• Galectin-3: a possible complementary marker to the PSA blood test

  2013cited by this paper
• Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy

  2013cited by this paper
• Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study

  2013cited by this paper
• Spondin-2 (SPON2), a More Prostate-Cancer-Specific Diagnostic Biomarker

  2012cited by this paper
• Evaluation of [−2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis

  2012cited by this paper
• Prostate cancer gene 3 urine assay cutoff in diagnosis of prostate cancer: a validation study on an Italian patient population undergoing first and repeat biopsy.

  2012cited by this paper
• Zinc α2‐glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer

  2012cited by this paper
• Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml

  2012cited by this paper
• Chronic prostatitis does not influence urinary PCA3 score

  2012cited by this paper
• Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer.

  2012cited by this paper
• Baseline prostate-specific antigen testing at a young age.

  2012cited by this paper
• Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases.

  2012cited by this paper
• Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion.

  2012cited by this paper
• EPCA-2: a highly specific serum marker for prostate cancer.

  2012cited by this paper
• 260 The cost-effectiveness of prostate cancer detection using Beckman Coulter Prostate Health Index

  2012cited by this paper
• Plasma sarcosine does not distinguish early and advanced stages of prostate cancer.

  2012cited by this paper
• Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden.

  2012cited by this paper
• Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers.

  2012cited by this paper
• International variation in prostate cancer incidence and mortality rates.

  2012cited by this paper
• Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC).

  2012cited by this paper
• Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.

  2011cited by this paper
• Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions.

  2011cited by this paper
• Contemporary role of prostate cancer gene 3 in the management of prostate cancer

  2011cited by this paper
• The Prostate 71 : 700 ^ 710 ( 2011 ) AMultiplexModelof CombiningGene-Based , Protein-Based , andMetabolite-BasedWith Positive andNegativeMarkers inUrine for the EarlyDiagnosis of ProstateCancer

  2011cited by this paper
• A multiplex model of combining gene‐based, protein‐based, and metabolite‐based with positive and negative markers in urine for the early diagnosis of prostate cancer

  2011cited by this paper
• A Three‐Gene panel on urine increases PSA specificity in the detection of prostate cancer

  2011cited by this paper
• Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial.

  2011cited by this paper
• A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range.

  2011cited by this paper
• Urine TMPRSS2:ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA

  2011cited by this paper
• Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression.

  2011cited by this paper
• Tumour markers in prostate cancer III: Biomarkers in urine

  2011cited by this paper
• Prostate cancer detection in the "grey area" of prostate-specific antigen below 10 ng/ml: head-to-head comparison of the updated PCPT calculator and Chun's nomogram, two risk estimators incorporating prostate cancer antigen 3.

  2011cited by this paper
• Surveillance for certain health behaviors among states and selected local areas - United States, 2008.

  2010cited by this paper
• A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France

  2010cited by this paper
• KLK15 is a prognostic marker for progression‐free survival in patients with radical prostatectomy

  2010cited by this paper
• Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test.

  2010cited by this paper
• Detection of complexes between prostate-specific antigen and protease inhibitors in plasma.

  2010cited by this paper
• Study of genetic and epigenetic alterations in urine samples as diagnostic markers for prostate cancer.

  2010cited by this paper
• Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection.

  2010cited by this paper
• Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours.

  2010cited by this paper
• External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome.

  2010cited by this paper
• Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication.

  2010cited by this paper
• Predictive value of PCA3 in urinary sediments in determining clinico‐pathological characteristics of prostate cancer

  2010cited by this paper
• Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

  2010cited by this paper
• A Prospective, Multicenter, National Cancer Institute Early Detection Research Network Study of [−2]proPSA: Improving Prostate Cancer Detection and Correlating with Cancer Aggressiveness

  2010cited by this paper
• Urine markers in monitoring for prostate cancer

  2010cited by this paper
• Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in Prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (≥ 100).

  2010cited by this paper
• Serum sarcosine is not a marker for prostate cancer

  2010cited by this paper
• PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial.

  2010cited by this paper
• The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free‐to‐total prostate‐specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies?

  2010cited by this paper
• [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study.

  2010cited by this paper
• New markers and multivariate models for prostate cancer detection.

  2009cited by this paper
• Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network.

  2009cited by this paper
• Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer

  2009cited by this paper
• Macrophage Inhibitory Cytokine 1: A New Prognostic Marker in Prostate Cancer

  2009cited by this paper
• Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram.

  2009cited by this paper
• A [‐2]proPSA‐based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases

  2009cited by this paper
• 297 FEASIBILITY AND CLINICAL UTILITY OF A TMPRSS2:ERG GENE FUSION URINE TEST

  2009cited by this paper
• Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression

  2009cited by this paper
• Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort

  2009cited by this paper
• Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer.

  2009cited by this paper
• A Multiparametric Serum Kallikrein Panel for Diagnosis of Non–Small Cell Lung Carcinoma

  2008cited by this paper
• A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy.

  2008cited by this paper

• Methylation-specific, universal, and highly sensitive identification of ctDNA in prostate cancer by multiplex droplet digital PCR

  2026cites this paper
• Risk factors of negative prostate biopsies: A CHAID decision tree analysis

  2026cites this paper
• Plasmonic Aluminum Thin Films as Substrate Materials for Label-Free Optical Detection and Surface-Enhanced MALDI Mass Spectrometry

  2025cites this paper
• A prognostic model for highly aggressive prostate cancer using interpretable machine learning techniques

  2025cites this paper
• Case Report: Stable disease achieved in a patient with metastatic castration-resistant prostate cancer following personalized treatment

  2025cites this paper
• Non-coding RNAs in Cancer: Mechanistic insights and therapeutic implications.

  2024cites this paper
• Prostate cancer biomarkers: from early diagnosis to precision treatment

  2024cites this paper
• Distance-based analytical device integrated with carbon nanomaterials for sarcosine quantification in human samples

  2024cites this paper
• Photothermal biosensing integrated with microfluidic paper-based analytical device for sensitive quantification of sarcosine.

  2024cites this paper
• Comprehensive diagnostic model of metastasis in prostate cancer: Individual and combined bioscore model of ADC value, Gleason score, and PSA

  2024cites this paper
• Unveiling the potential of SLURP1 protein as a biomarker for prostate cancer screening.

  2024cites this paper
• Natural Protein Photon Upconversion Supramolecular Assemblies for Background-Free Biosensing.

  2024cites this paper
• Frontiers in mass spectrometry–based clinical proteomics for cancer diagnosis and treatment

  2023cites this paper
• Emerging Hallmarks of Metabolic Reprogramming in Prostate Cancer

  2023cites this paper
• Study on Early Prostate Cancer Antigen (EPCA) and existent risk factors of prostate cancer, Sudan: A case-control study

  2023cites this paper
• The Role of Fascin-1 in Human Urologic Cancers: A Promising Biomarker or Therapeutic Target?

  2023influential citation
• The Bone Microenvironment Soil in Prostate Cancer Metastasis: An miRNA Approach

  2023cites this paper
• Correlations between serum levels of microRNA-148a-3p and microRNA-485-5p and the progression and recurrence of prostate cancer

  2022cites this paper
• Oncoproteomics: insight into current proteomic technologies in cancer biomarker discovery and treatment

  2022cites this paper
• Silica Nanospheres Coated Silver Islands as an Effective Opto-Plasmonic SERS Active Platform for Rapid and Sensitive Detection of Prostate Cancer Biomarkers

  2022cites this paper
• Urinary marker panels for aggressive prostate cancer detection

  2022cites this paper
• Understanding of PSA biology, factors affecting PSA detection, challenges, various biomarkers, methods, and future perspective of prostate cancer detection and diagnosis

  2022cites this paper
• Circulating metabolite biomarkers: a game changer in the human prostate cancer diagnosis

  2022cites this paper
• Glycosylation in cancer: its application as a biomarker and recent advances of analytical techniques

  2022cites this paper
• Semen as a rich source of diagnostic biomarkers for prostate cancer: latest evidence and implications

  2021cites this paper
• ICPMS based multiplexed bioassay: Principles, approaches and progresses

  2021cites this paper
• Proteolyzed Variant of IgG with Free C-Terminal Lysine as a Biomarker of Prostate Cancer

  2021cites this paper
• Development of electronic modules for their integration with impedimetric transducers applied to sarcosine detection

  2021cites this paper
• Serum levels of total and urine level of PCA3 in patients with benign prostatic hyperplasia and prostate cancer.

  2020cites this paper
• The Percentage of Free PSA and Urinary Markers Distinguish Prostate Cancer from Benign Hyperplasia and Contribute to a More Accurate Indication for Prostate Biopsy

  2020cites this paper
• A 2 M ( alpha-2-macroglobulin )

  2020cites this paper
• Circulating let-7f-5p improve risk prediction of prostate cancer in patients with benign prostatic hyperplasia

  2020cites this paper
• Identification of Clinically Significant Prostate Cancer by Combined PCA3 and AMACR mRNA Detection in Urine Samples

  2020cites this paper
• Towards the differential diagnosis of prostate cancer by the pre-treatment of human urine using ionic liquids

  2020cites this paper
• Explorative analysis of a predictive score for patients with metastatic, castration resistant prostate cancer undergoing radioligand therapy with [177Lu]Lu-labeled prostate-specific membrane antigen

  2020cites this paper
• Can the combination of biparametric magnetic resonance imaging and PSA‐related indicators predict the prostate biopsy outcome?

  2020cites this paper
• Highly sensitive impedimetric immunosensor for determination of interleukin 6 as a cancer biomarker by using conjugated polymer containing epoxy side groups modified disposable ITO electrode.

  2020cites this paper
• Explorative analysis of a score predicting the therapy response of patients with metastatic, castration resistant prostate cancer undergoing radioligand therapy with 177Lu-labeled prostate-specific membrane antigen

  2020cites this paper
• Prediction models for prostate cancer to be used in the primary care setting: a systematic review

  2020cites this paper
• Development of a glycoproteomic strategy to detect more aggressive prostate cancer using lectin-immunoassays for serum fucosylated PSA

  2019cites this paper
• An electrochemical biosensor for prostate cancer biomarker detection using graphene oxide–gold nanostructures

  2019cites this paper
• The role of protein tyrosine phosphatases in prostate cancer biology.

  2019cites this paper
• Tumor‐Derived Extracellular Vesicles as a Novel Source of Protein Biomarkers for Cancer Diagnosis and Monitoring

  2019cites this paper
• High-sensitivity lateral flow immunoassay with a fluorescent lanthanide nanoparticle label.

  2019cites this paper
• Pancreatic cancer biomarker detection by two support vector strategies for recursive feature elimination.

  2019cites this paper
• How is the association between urinary prostate cancer antigen 3 (PCA3) levels and Gleason scores in patients suspicious of prostate cancer?

  2019influential citation
• Graphene-based biosensors for the detection of prostate cancer protein biomarkers: a review

  2019cites this paper
• In silico analysis of non-synonymous single nucleotide polymorphism in a human KLK-2 gene associated with prostate cancer

  2019cites this paper
• Searching for the Novel Specific Predictors of Prostate Cancer in Urine: The Analysis of 84 miRNA Expression

  2018cites this paper
• Application of Biomarkers and Biosensors to Detect and Track Pathogenic Agents

  2018cites this paper
• Development of an impedimetric sensor for the label-free detection of the amino acid sarcosine with molecularly imprinted polymer receptors

  2017cites this paper
• Gamma-glutamyltransferase activity in exosomes as a potential marker for prostate cancer

  2017cites this paper
• Prostate cancer proteomics: Current trends and future perspectives for biomarker discovery

  2017cites this paper
• Urinary Biomarker Panel to Improve Accuracy in Predicting Prostate Biopsy Result in Chinese Men with PSA 4–10 ng/mL

  2017cites this paper
• Matrix metalloproteinase and heparin-stimulated serine proteinase activities in post-prostate massage urine of men with prostate cancer.

  2017cites this paper
• Analysis of Fascin-1 in Relation to Gleason Risk Classification and Nuclear ETS-Related Gene Status of Human Prostate Carcinomas: An Immunohistochemical Study of Clinically Annotated Tumours From the Wales Cancer Bank

  2017cites this paper
• Tumour‐associated antigens and their anti‐cancer applications

  2017cites this paper
• LncRNA UCA1 in anti-cancer drug resistance

  2017cites this paper
• Exosomes in semen: opportunities as a new tool in prostate cancer diagnosis

  2017cites this paper
• MicroRNA-27a-5p Regulation by Promoter Methylation and MYC Signaling in Prostate Carcinogenesis

  2017cites this paper
• The characterization of 17β-hydroxysteroid dehydrogenase type 2 (17βHSD2) activity towards novel C19 substrates.

  2017influential citation
• Utilização de ressonância plasmônica de superfície como ferramenta analítica para detecção de biomarcadores

  2017cites this paper
• Single Molecule Upconversion-Linked Immunosorbent Assay with Extended Dynamic Range for the Sensitive Detection of Diagnostic Biomarkers.

  2017cites this paper
• Adams, J. (2017). Analysis of Fascin-1 in Relation to Gleason Risk Classification and Nuclear ETS-Related Gene Status of Human Prostate Carcinomas: An Immunohistochemical Study of Clinically Annotated Tumours From the Wales Cancer Bank. Biomarkers in Cancer, 9, [1179299X17710944]. https://doi.org/10

  2017cites this paper
• Clarke, A. R. (2017). Analysis of Fascin-1 in Relation to Gleason Risk Classification and Nuclear ETS-Related Gene Status of Human Prostate Carcinomas: An Immunohistochemical Study of Clinically Annotated Tumours From the Wales Cancer Bank. Biomarkers, 9, [1179299X17710944]. DOI: 10.1177/1179299X177

  2017cites this paper
• Localized Surface Plasmon Resonance Biosensor for Detection of Serum Prostate Specific Antigen in Prostate Cancer Patients

  2016cites this paper
• Urothelial cancer associated 1: a long noncoding RNA with a crucial role in cancer

  2016cites this paper
• Urinary Biomarkers for Prostate Cancer.

  2016cites this paper
• Prostasomes as a source of diagnostic biomarkers for prostate cancer.

  2016cites this paper
• Novel potential serological prostate cancer biomarkers using CT100+ cancer antigen microarray platform in a multi-cultural South African cohort

  2016cites this paper
• EPCA2.22: A Silver Lining for Early Diagnosis of Prostate Cancer.

  2016cites this paper
• Improvement of Prostate Cancer Diagnosis by Detecting PSA Glycosylation-Specific Changes

  2016influential citation
• Prostate cancer antigen 3 moderately improves diagnostic accuracy in Chinese patients undergoing first prostate biopsy

  2016cites this paper
• Highly-trained dogs’ olfactory system for detecting biochemical recurrence following radical prostatectomy

  2016cites this paper
• Urinary miR-183 and miR-205 do not surpass PCA3 in urine as predictive markers for prostate biopsy outcome despite their highly dysregulated expression in prostate cancer tissue

  2015cites this paper
• Quantifying Gleason scores with photoacoustic spectral analysis: feasibility study with human tissues.

  2015cites this paper
• Oxidative stress measured by thioredoxin reductase level as potential biomarker for prostate cancer.

  2015cites this paper
• High PCA3 scores in urine correlate with poor-prognosis factors in prostate cancer patients.

  2015cites this paper
• Urine metabolic fingerprinting using LC-MS and GC-MS reveals metabolite changes in prostate cancer: A pilot study.

  2015cites this paper
• Current State of ERG as Biomarker in Prostatic Adenocarcinoma.

  2015cites this paper
• Original Article Oxidative stress measured by thioredoxin reductase level as potential biomarker for prostate cancer

  2015cites this paper
• Prostate-specific RNA aptamer: promising nucleic acid antibody-like cancer detection

  2015cites this paper
• Mass Spectrometry-Based Approaches for Targeted Quantitative Proteomics in Biomarker Development

  2015cites this paper
• Original Article High PCA3 scores in urine correlate with poor-prognosis factors in prostate cancer patients

  2015cites this paper
• Tumor Markers Currently Utilized in Cancer Care

  2015cites this paper
• Micrornas as predictors and therapy for prostate cancer

  2015cites this paper
• THIOREDOXIN REDUCTASE AS BIOMARKER FOR DIFFERENTIAL DIAGNOSIS OF PROSTATE CANCER

  2015cites this paper
• The Ability of Dogs to Detect Human Prostate Cancer Before and After Radical Prostatectomy

  2015cites this paper
• Prostate cancer screening in Primary Health Care: the current state of affairs

  2015influential citation
• Potential Utility of Novel Biomarkers in Active Surveillance of Low-Risk Prostate Cancer

  2015cites this paper
• High PCA 3 scores in urine correlate with poor-prognosis factors in prostate cancer patients

  2015cites this paper
• Sniffing out prostate cancer: a new clinical opportunity

  2015cites this paper
• Current biomarkers for diagnosing of prostate cancer.

  2015cites this paper
• Urinary thiosulfate as failed prostate cancer biomarker – an exemplary multicenter re-evaluation study

  2015cites this paper
• Metabolomic profiling for the identification of novel diagnostic markers in prostate cancer

  2015cites this paper
• Cancer Cell-Specific Oligopeptides Selected by an Integrated Microfluidic System from a Phage Display Library for Ovarian Cancer Diagnosis

  2015cites this paper
• Two-dimensional neovascular complexity is significantly higher in nontumor prostate tissue than in low-risk prostate cancer

  2015cites this paper
• The highs and lows of tumor biomarkers: lost illusions

  2015cites this paper
• Pathway analysis of genome-wide association study on serum prostate-specific antigen levels.

  2014cites this paper
• Substrate gelatin zymogrophy analysis of matrix metalloproteinase-2 and -9 (gelatinase A and B) in sera from patients with benign and malignant prostate disease

  2014cites this paper